A practical reference on CJC-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
=== Transvaal stayaway: 5–6 November 1984 === On 27 October, at a meeting of 37 political, civic, and labour organisations in Johannesburg, COSAS reiterated a prior call for workers to support the youth's demands and oppose the heavy-handed state response to the uprising. The meeting resolved to form an ad hoc joint committee, the Transvaal Regional Stay-Away Committee, which would coordinate a two-day stay-away. In a major development, trade unions – notably the largest union, the Federation of South African Trade Unions, but also the Council of Mining Unions and the Metal and Allied Workers' Union – overcame their prevailing tendency towards to political "absenteeism" and participated. The stay-away, held on 5 to 6 November, was a resounding success. On competing estimates, between 40 per cent and 60 per cent of workers in Johannesburg did not attend work on the first day, and the government said that 250,000 students had not attended school. On the second day, the figures were even higher, including an estimated 90 per cent of workers in Vaal, 85 per cent on the East Rand, and 66 per cent in Soweto. That evening, Sasol, the state-owned energy corporation, announced that it had fired 90 per cent of its workforce – 6,000 workers – for participating. The work-stoppage was accompanied in some areas by further violence and arson, met by police tear gas and rubber bullets; ten people were reported killed on the first day and a further seven on the second.
== References == This article was adapted from the following source under a CC BY 4.0 license (2021) (reviewer reports): Yingxuan Ma; Kim Johnson (2021). "Arabinogalactan-proteins" (PDF). WikiJournal of Science. 4 (1): 2. doi:10.15347/wjs/2021.002. Wikidata Q99557488.
Contamination has also been seen in water wells and other sources of drinking water. This contamination is seen in US, United Kingdom, Germany, Japan, and Canada, but information from most developing countries is nearly nonexistent. The lack of information on PFAS contamination in developing countries, especially those in Africa, are due to structural socioeconomic inequality and lack of access to the expensive laboratory capabilities required for PFAS quantification.
Russia claimed that a Ukrainian drone attack set fire to energy infrastructure in Smolensk Oblast. A drone struck an industrial area in Lipetsk Oblast without details on injuries or damage caused, while an oil refinery was also struck in Voronezh Oblast, causing a fire. Ukrainian sources claimed that some 26,000 cubic metres of fuel was destroyed. The Ukrainian government issued a decree banning the delivery of identification documents and passports to Ukrainian men of military age abroad. The SBU formally announced that Metropolitan Arsenii, the UOC-MP head of the Sviatohirsk Lavra in Donetsk Oblast, was under suspicion of spying for Russia for divulging Ukrainian military positions during a public liturgy. Ukraine received another tranche of 1.5 billion euros in funds from the EU. President Biden signed into law the aid package for Ukraine. The US Department of Defense subsequently announced a $1 billion package that included HIMARS systems, artillery rounds, air defense missiles and Bradley IFVs. A Russian court ordered the seizure of $439.5 million in funds from JPMorgan Chase to recoup losses from US sanctions.
Screening tests are offered to the asymptomatic people to reveal possible diseases. On the contrary, diagnostic tests are used to prove or disapprove certain conditions. To follow the course of the disease or the reaction to treatment, monitoring tests are presented. Lastly, there are tests during the follow-up to determine the results following treatment. The following is an example of a typical breakdown of the responsibilities of each area:
Sources: en.wikipedia.org
=== Cancer research === There is research investigating whether high dose intravenous vitamin C administration as a co-treatment will suppress cancer stem cells, which are responsible for tumor recurrence, metastasis and chemoresistance.
==== Canaloplasty ==== Canaloplasty is a nonpenetrating procedure using microcatheter technology. To perform a canaloplasty, an incision is made into the eye to gain access to the Schlemm's canal, similarly to a viscocanalostomy. A microcatheter will circumnavigate the canal around the iris, enlarging the main drainage channel and its smaller collector channels through the injection of a sterile, gel-like material called viscoelastic. The catheter is then removed, and a suture is placed within the canal and tightened. By opening the canal, the pressure inside the eye may be relieved, although the reason is unclear, since the canal (of Schlemm) does not have any significant fluid resistance in glaucoma or healthy eyes. Long-term results are not available.
Type VII was the first recessive OI type confirmed, initially found among First Nations people in Quebec. Type VIII – OI caused by a mutation in the gene LEPRE1 on chromosome 1p34.2; clinically similar to OI types II and III, depending on affected individual. Type IX – OI caused by homozygous or compound heterozygous mutation in the PPIB gene on chromosome 15q22.31. Type X – OI caused by homozygous mutation in the SERPINH1 gene on chromosome 11q13. Type XI – OI caused by mutations in FKBP10 on chromosome 17q21. The mutations cause a decrease in the secretion of trimeric procollagen molecules. Other mutations in this gene can cause autosomal recessive Bruck syndrome, which is similar to OI. Type XII – OI caused by a frameshift mutation in SP7 on chromosome 12q13.13. This mutation causes bone deformities, fractures, and delayed tooth eruption. Type XIII – OI caused by a mutation in the bone morphogenetic protein 1 (BMP1) gene on chromosome 8p21.3. This mutation causes recurrent fractures, high bone mass, and hypermobile joints. Type XIV – OI caused by mutations in the TMEM38B gene on chromosome 9q31.2. This mutation causes recurrent fractures and osteopenia, although the disease trajectory is highly variable. Type XV – OI caused by homozygous or compound heterozygous mutations in the WNT1 gene on chromosome 12q13.12. It is autosomal recessive. Type XVI – OI caused by mutations in the CREB3L1 gene on chromosome 11p11.2.
== Production == Reactor-grade plutonium from spent nuclear fuel contains various isotopes of plutonium. 238Pu makes up only one or two percent, but it may be responsible for much of the short-term decay heat because of its short half-life relative to other plutonium isotopes. Reactor-grade plutonium is not useful for producing 238Pu for RTGs because difficult isotopic separation would be needed. Pure plutonium-238 is prepared by neutron irradiation of neptunium-237, one of the minor actinides that can be recovered from spent nuclear fuel during reprocessing, or by the neutron irradiation of americium in a reactor. The targets are purified chemically, including dissolution in nitric acid to extract the plutonium-238. A 100 kg sample of light water reactor fuel that has been irradiated for three years contains only about 700 grams (0.7% by weight) of neptunium-237, which must be extracted and purified. In the US, the Department of Energy's Space and Defense Power Systems Initiative of the Office of Nuclear Energy processes 238Pu, maintains its storage, and develops, produces, transports and manages safety of radioisotope power and heating units for both space exploration and national security spacecraft. As of March 2015, a total of 35 kilograms (77 pounds) of 238Pu was available for civil space uses. Out of the inventory, 17 kg (37 lb) remained in a condition meeting NASA specifications for power delivery.
The Trump administration took the unusual step of subjecting approximately 50 members of the US military's Joint Chiefs of Staff to polygraph tests over leaks to journalists, including information about how the war has resulted in a shortage of critical munitions. Early attacks on US bases caused logistics issues in US aircraft carrier USS Abraham Lincoln. The Pentagon has transferred weapons stored in Asia and Europe to replenish stockpiles in the Middle East. Still, missile interceptors shortage reportedly persuaded Trump to call off a planned major attack on Iran. The Trump administration blames the shortage on Joe Biden giving too many weapons to Ukraine. On 17 September, Lockheed Martin received the first batch of Patriot interceptor parts from General Motors less than a month after the two companies signed a manufacturing agreement, in a success for the Pentagon's push for faster weapon production, particularly the Patriot missile defense system, as it remained one of the world's most sought-after weapons for the war and Russia's war in Ukraine.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.